Celyad Oncology SA
Clinical-stage biotech developing CAR T therapies for solid and blood cancers.
CYAD | BR
Overview
Corporate Details
- ISIN(s):
- BE0974260896 (+2 more)
- LEI:
- 549300ORR0M8XF56OI64
- Country:
- Belgium
- Address:
- RUE ANDRE DUMONT 9, 1435 MONT-SAINT-GUIBERT
- Website:
- https://celyad.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Celyad Oncology SA is a clinical-stage biotechnology company that specializes in the discovery and development of Chimeric Antigen Receptor T-cell (CAR T) therapies for cancer treatment. The company focuses on pioneering advanced technologies to create a pipeline of both allogeneic (off-the-shelf) and autologous (patient-derived) CAR T-cell candidates. Celyad's differentiated strategy aims to broaden the range of treatable cancer indications, including hematological malignancies and solid tumors, while addressing the primary limitations of existing CAR T-cell therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-04 00:00 |
Declaration of Voting Results & Voting Rights Announcements
20250904_PR_Double-voting-rights.ENG_Website.pdf
|
English | 154.5 KB | ||
| 2025-09-04 00:00 |
Declaration of Voting Results & Voting Rights Announcements
20250904_PR_Double-droit-de-vote.FR_Website.pdf
|
French | 91.2 KB | ||
| 2025-08-26 08:30 |
Regulatory Filings
20250826_PR_R&D discontinuation ENG.FINAL.clean.pdf
|
English | 176.9 KB | ||
| 2025-08-26 08:30 |
Regulatory Filings
20250826_PR_Arret R&D FR.FINAL.pdf
|
French | 162.6 KB | ||
| 2025-08-13 00:00 |
Major Shareholding Notification
20250913_PR_Fortress Transparency Notification ENG.Final.pdf
|
English | 238.9 KB | ||
| 2025-08-13 00:00 |
Major Shareholding Notification
20250913_PR_Fortress Transparency Notification FR.Final.pdf
|
French | 224.1 KB | ||
| 2025-08-07 00:00 |
Declaration of Voting Results & Voting Rights Announcements
20250807 PR_Total Number of Voting Rights and Shares_ENG.3.pdf
|
English | 106.6 KB | ||
| 2025-08-07 00:00 |
Declaration of Voting Results & Voting Rights Announcements
20250807 PR_Total Number of Voting Rights and Shares_FR.2.pdf
|
French | 110.9 KB | ||
| 2025-08-07 00:00 |
Declaration of Voting Results & Voting Rights Announcements
20250807 PR_Total Number of Voting Rights and Shares_ENG.3.pdf
|
English | 106.6 KB | ||
| 2025-08-07 00:00 |
Declaration of Voting Results & Voting Rights Announcements
20250807 PR_Total Number of Voting Rights and Shares_FR.2.pdf
|
French | 110.9 KB | ||
| 2025-08-05 00:00 |
AGM Information
PV Notaire.5août2025.signed.pdf
|
French | 334.3 KB | ||
| 2025-08-05 00:00 |
Audit Report / Information
CELYAD_ Rapport de Commissaire - Augm de K 1 MEUR_VDEF_SIGNED_280725.pdf
|
French | 150.8 KB | ||
| 2025-08-05 00:00 |
Share Issue/Capital Change
FR_Celyad_Rapport Special du CA_PIPE2025_23juillet2025.FE.pdf
|
French | 2.6 MB | ||
| 2025-08-05 00:00 |
Share Issue/Capital Change
20250724_CYAD-PR-PIPE-ENG.2.pdf
|
English | 113.4 KB | ||
| 2025-08-05 00:00 |
Share Issue/Capital Change
20250724_CYAD-PR-PIPE-FR.2.pdf
|
French | 86.4 KB |
Automate Your Workflow. Get a real-time feed of all Celyad Oncology SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Celyad Oncology SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celyad Oncology SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-28 | Kane Matthew | Board | Other | 1,035,714 | 279,642.78 EUR |
| 2024-11-26 | Piscitelli Dominic | Board | Other | 10,000 | 2,700.00 EUR |
| 2024-11-25 | Iserentant Hannes | Executive member | Other | 30,000 | 8,100.00 EUR |
| 2024-11-22 | Phan An | Executive member | Other | 30,000 | 8,100.00 EUR |
| 2024-11-06 | Goblet Serge | Board | Other | 10,000 | 2,700.00 EUR |
| 2024-11-05 | Udier Blagovic Marina | Board | Other | 10,000 | 2,700.00 EUR |
Peer Companies
